Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Neoplasms
/ drug therapy
Child
Cisplatin
/ administration & dosage
Cohort Studies
Doxorubicin
/ administration & dosage
Female
Follow-Up Studies
Humans
Male
Methotrexate
/ administration & dosage
Neoplasm Metastasis
Osteosarcoma
/ drug therapy
Prognosis
Survival Rate
Chemotherapy
Cohort
Osteosarcoma
Outcomes
Surgery
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
12
09
2018
revised:
12
11
2018
accepted:
16
11
2018
pubmed:
28
1
2019
medline:
22
5
2020
entrez:
28
1
2019
Statut:
ppublish
Résumé
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients. For all registered patients at a median follow-up of 54 months (interquartile range: 38-73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57-61%) and 54% (95% CI: 52-56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95-2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38-2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10-2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77-81%) and 71% (95% CI: 68-73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76-2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome. In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.
Sections du résumé
BACKGROUND
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials.
METHODS
Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients.
RESULTS
For all registered patients at a median follow-up of 54 months (interquartile range: 38-73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57-61%) and 54% (95% CI: 52-56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95-2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38-2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10-2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33-0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52-0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77-81%) and 71% (95% CI: 68-73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76-2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome.
CONCLUSIONS
In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.
Identifiants
pubmed: 30685685
pii: S0959-8049(18)31534-X
doi: 10.1016/j.ejca.2018.11.027
pmc: PMC6506906
pii:
doi:
Substances chimiques
Doxorubicin
80168379AG
Cisplatin
Q20Q21Q62J
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-50Subventions
Organisme : Medical Research Council
ID : MC_UU_12023/28
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA106450
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
J Clin Oncol. 2000 Dec 15;18(24):4016-27
pubmed: 11118462
J Clin Oncol. 2002 Feb 1;20(3):776-90
pubmed: 11821461
Eur J Cancer. 2002 Jun;38(9):1218-25
pubmed: 12044509
J Clin Oncol. 2003 May 15;21(10):2011-8
pubmed: 12743156
Eur J Cancer. 2003 Mar;39(4):488-94
pubmed: 12751380
J Clin Oncol. 2005 Mar 20;23(9):2004-11
pubmed: 15774791
Cancer. 2006 Mar 1;106(5):1154-61
pubmed: 16421923
J Clin Oncol. 2006 Mar 1;24(7):1161-8
pubmed: 16505436
Eur J Cancer. 2007 Mar;43(4):752-61
pubmed: 17267204
J Clin Oncol. 2008 Feb 1;26(4):633-8
pubmed: 18235123
J Surg Oncol. 2008 Nov 1;98(6):415-20
pubmed: 18792969
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Cancer Treat Res. 2009;152:289-308
pubmed: 20213397
Cancer Treat Res. 2009;152:339-53
pubmed: 20213400
Ann Oncol. 2012 Jun;23(6):1607-16
pubmed: 22015453
Cancer. 2012 Sep 15;118(18):4597-605
pubmed: 22252521
J Clin Oncol. 2012 Jun 10;30(17):2112-8
pubmed: 22564997
J Clin Oncol. 2013 Jun 20;31(18):2303-12
pubmed: 23669227
Histopathology. 2014 Jan;64(1):2-11
pubmed: 24164390
Pediatr Blood Cancer. 2014 May;61(5):840-5
pubmed: 24254749
Acta Oncol. 2015 Jan;54(1):25-33
pubmed: 24957555
Ann Oncol. 2015 Feb;26(2):407-14
pubmed: 25421877
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
J Cancer Res Clin Oncol. 2016 Oct;142(10):2197-207
pubmed: 27469493
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442
Eur J Cancer. 1994;30A(5):620-6
pubmed: 8080676
J Clin Oncol. 1993 Mar;11(3):449-53
pubmed: 8445419
Ann Oncol. 1998 Aug;9(8):893-9
pubmed: 9789613